Lancashire and South Cumbria
Formulary
 
back
10 Musculoskeletal and joint diseases

This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net. 

For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/

10-01-04 Long-term control of gout

Allopurinol
First Choice
Tablets 100mg, 300mg

Green View adult BNF  View SPC online  View childrens BNF
Febuxostat
Second Choice

Tablets 80mg, 120mg

For patients who are intolerant of allopurinol or for whom allopurinol is contraindicated.
Link  MHRA: Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity
Link  MHRA: Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease

Green View adult BNF  View SPC online  View childrens BNF